There are no products listed under this category.
ADAMTS17
ADAMTS17 (a disintegrin and metalloproteinase with thrombospondin motifs 17) is a secreted extracellular metalloprotease of the ADAMTS family. It regulates skeletal development by modulating BMP-SMAD signalling and the organisation of extracellular matrix microfibrils. Browse Assay Genie's current range of ADAMTS17 research reagents below, or read on for the biology behind the target.
ADAMTS17 is an extracellular metalloprotease that regulates skeletal development. It does so by modulating BMP-SMAD signalling and the organisation of extracellular matrix microfibrils, which in turn controls chondrocyte differentiation and bone growth. The protein is secreted and sits in the extracellular space and extracellular matrix, where it acts on its surroundings rather than inside the cell.
The ADAMTS17 gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, listed by HGNC in the group of ADAM metallopeptidases with thrombospondin type 1 motif. Family members share several protein modules: a propeptide region, a metalloproteinase domain, a disintegrin-like domain and a thrombospondin type 1 (TS) motif. Individual members differ in the number of C-terminal TS motifs, and some carry unique C-terminal domains. The encoded preproprotein is proteolytically processed to generate the mature protein. The mouse ortholog is Adamts17.
The gene has previously been known as FLJ32769 and FLJ16363, and its earlier name was a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 17. Mutations in the gene are associated with a Weill-Marchesani-like syndrome, characterised by lenticular myopia, ectopia lentis, glaucoma, spherophakia and short stature. The mature protein may also promote breast cancer cell growth and survival, which makes it of interest beyond skeletal and ocular biology.
ADAMTS17 regulates skeletal development, controlling chondrocyte differentiation and bone growth, so it is a useful target for studying how the matrix shapes bone formation.
The protease modulates BMP-SMAD signalling, making it relevant to work on how extracellular enzymes tune growth factor pathways.
ADAMTS17 influences the organisation of extracellular matrix microfibrils, which supports studies of matrix assembly and remodelling.
Mutations in ADAMTS17 are associated with a Weill-Marchesani-like syndrome involving ectopia lentis, glaucoma and short stature.
ADAMTS17 is a secreted extracellular metalloprotease that regulates skeletal development. It modulates BMP-SMAD signalling and the organisation of extracellular matrix microfibrils, thereby controlling chondrocyte differentiation and bone growth. The NCBI summary also notes the mature protein may promote breast cancer cell growth and survival.
The HGNC name is ADAM metallopeptidase with thrombospondin type 1 motif 17, and UniProt lists a disintegrin and metalloproteinase with thrombospondin motifs 17. Earlier symbols are FLJ32769 and FLJ16363. The protein is made as a preproprotein that is proteolytically processed into the mature form.
Mutations in the ADAMTS17 gene are associated with a Weill-Marchesani-like syndrome, with lenticular myopia, ectopia lentis, glaucoma, spherophakia and short stature. A mouse ortholog, Adamts17, exists; check the datasheet of any product for its validated reactivity.
Other ADAMTS family metalloproteases involved in extracellular matrix biology, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q8TE56; product specifications from Assay Genie datasheets.
There are no products listed under this category.